The short-term effects of Eudragit-L-coated prednisolone metasulphobenzoate (Predocol) on bone formation and bone mineral density in acute ulcerative colitis

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 11, 2004, Pages 1173-1176

  Darlow, Simon J ^a   Mandal, Aditya ^b   Pick, Barbara ^a   Thomas, Titus ^a   Mayberry, John F ^b   Robinson, Richard J ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bone mineral density; Disease activity; Predocol; Ulcerative colitis

Indexed keywords

EUDRAGIT; OSTEOCALCIN; PREDNISOLONE 3 SULFOBENZOATE; PREDOCOL;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG COATING; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HIP; HUMAN; LONGITUDINAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; SCORING SYSTEM; SPINE; ULCERATIVE COLITIS;

ACUTE DISEASE; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BONE DENSITY; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOGENESIS; POLYMETHACRYLIC ACIDS; PREDNISOLONE; TREATMENT OUTCOME;

EID: 8444240796     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200411000-00015     Document Type: Article

References (15)

1. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population based cohort study. Annals Int Med 2000; 133:828-830.
2. Compston JE, Judd D, Crawley EO, Evans DW, Evans C, Church AH, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28:410-415.
3. Bressot C, Meunier PJ, Chapuy MC, Lejune E, Edouard C, Darby AJ. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Relat Res 1979; 1:303-311.
4. Prummel MF, Wiersinga WM, Lips P, Sanders GTB, Sauerwein HP. The course of biochemical markers of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991; 72:382-386.
5. Pearce G, Tabensky AD, Delmas DP, Gordon Baker WH, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83:801-806.
6. Lee D, Taylor M, James VHT, Walker G. Rectally administered prednisolone - evidence for a predominantly local action. Gut 1980; 21: 215-218.
7. Ford GA, Oliver PS, Wilkinson SP. A Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use. Aliment Pharmacol Ther 1992; 6:31-40.
8. Bell GD, English J, Spiers C, Nylander D, Hancock JM, Rowland RS. Colonic mucosal concentrations of prednisolone following oral administration of a novel formulation of prednisolone metasulphobenzoate (Predocol) [Abstract]. Gut 2000; 46:T29.
9. Powell-Tuck J, Lennard-Jones JE, May CS, Wilson CG, Paterson JW. Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis. Br Med J 1976; i:193-195.
10. Truelove SC, Witts CJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; ii:1041-1048.
11. Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of bone loss after menopause. J Bone Miner Res 2000; 15:1398-1404.
12. Aaron JK, Francis RM, Peacock M, Makins NB. Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthop Rel Res 1989; 243:294-305.
13. Gundberg CM, Nishimoto SK. Vitamin K dependent proteins of bone and cartilage. In: Seibel M, Robins S, Bilezikan J (editors): Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Applications. San Diego: Academic Press; 1999, p. 43.
14. Kotowicz MA, Hall S, Hunder GG, Cedel LS, Mann GK, Riggs LB. Relationship of glucocorticoid dosage to serum bone g1a protein concentration in patients with rheumatological disorders. Arthritis Rheum 1990; 33:1487-1491.
15. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheum 1994; 33:348-350.